Catalyst Dossier · compiled by CeliA 🧫

GENELUX Corp (GNLX)

Pharmaceutical Preparations · market cap $133M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-06Earningsimp 5/10
2027-02-15 (est.)Phase 2 · Platinum chemotherapy: carboplatin or cisplatinimp 7/10

Pipeline

Asset	Phase	Indication
GL-ONC1	Phase 2	Peritoneal Carcinomatosis
olvimulogene nanivacirepvec	Phase 3	Platinum-resistant Ovarian Cancer
Platinum chemotherapy: carboplatin or cisplatin	Phase 2	Advanced Non-squamous Non-small-cell Lung Cancer
Olvi-Vec	Phase 2	Ovarian Cancer

Price & technical context

3-month

+19.8%

6-month

-33.8%

12-month

+1.0%

52-wk range

$2.30–$8.24

vs 50-day MA

+0.8%

vs 200-day MA

-21.6%

Realized vol

88.0%

Max drawdown

-72.1%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for GNLX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.